# Phase 1 Carcinoma, Non-Small-Cell Lung trials: 205 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 205 trials in phase 1 for Carcinoma, Non-Small-Cell Lung that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Carcinoma, Non-Small-Cell Lung trials: 205 rows for $10.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/carcinoma-non-small-cell-lung

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 205
- Recruiting or not yet: 205
- Read on: November 19, 2026

## Trials

The 25 newest of 205, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 16, 2026 | NCT07938463 | Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | Dana-Farber Cancer Institute | Phase 1 | Not yet recruiting | ALK Positive Non-small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938463) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 3, 2026 | NCT07912268 | Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912268) |
| November 2, 2026 | NCT07910942 | A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer | Kanvas Biosciences | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910942) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 28, 2026 | NCT07899801 | A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Non Small Cell Lung Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899801) |
| October 27, 2026 | NCT07899086 | A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899086) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 22, 2026 | NCT07890246 | A Phase 1 Study of IM-1340 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Not yet recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890246) |
| October 22, 2026 | NCT07887971 | A Study of \[225Ac\]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate... | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887971) |
| October 21, 2026 | NCT07886229 | Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer | Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Resectable Non-Small-Cell Lung Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886229) |
| October 5, 2026 | NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non... | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857616) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 8, 2026 | NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With... | AbbVie | Phase 1 | Recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807956) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| September 3, 2026 | NCT07801508 | A Study of \[68Ga\]Ga-DWJ155 in Adult Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801508) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| July 13, 2026 | NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699757) |
| June 23, 2026 | NCT07663630 | A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss | Pfizer | Phase 1 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC), Cachexia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663630) |
| June 22, 2026 | NCT07660055 | Study of \[177Lu\]Lu-DWJ155 and \[68Ga\]Ga-DWJ155 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660055) |
| June 16, 2026 | NCT07650357 | A Study of CLSP 5282 in HLA-A\*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | Clasp Therapeutics, Inc. | Phase 1 | Not yet recruiting | Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650357) |
| June 16, 2026 | NCT07649200 | Study of SNH-118110 in Advanced Solid Tumors | ScinnoHub Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Solid Tumors | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649200) |
| June 5, 2026 | NCT07630961 | Phase I Study of JFI447 \[68Ga\]Ga-DFC413 and Comparison to FFG233 \[68Ga\]Ga-NNS309 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630961) |
| June 3, 2026 | NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 1 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid... | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624214) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 6 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 6 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 4 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 3 |
| M.D. Anderson Cancer Center | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| City of Hope Medical Center | 3 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 3 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 3 |
| SystImmune Inc. | 3 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| University of Pennsylvania | 2 |
| University of California, Davis | 2 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 2 |
| West China Hospital | 2 |
| Aktis Oncology, Inc. | 2 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Myeloid Therapeutics | 2 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 2 |
| Kumquat Biosciences Inc. | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Sichuan University | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 115 |
| China | 65 |
| Spain | 29 |
| Australia | 25 |
| France | 23 |
| Canada | 22 |
| South Korea | 19 |
| Japan | 18 |
| United Kingdom | 16 |
| Italy | 13 |
| Netherlands | 9 |
| Belgium | 9 |
| Germany | 9 |
| Israel | 8 |
| Taiwan | 7 |
| Poland | 4 |
| Denmark | 4 |
| Switzerland | 3 |
| Singapore | 3 |
| Austria | 2 |
| Georgia | 2 |
| Ireland | 2 |
| Portugal | 2 |
| Brazil | 2 |
| Hong Kong | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
